Craig West
Senior Vice President, Investor Relations
Replay available
Nanobiotix S.A. (NASDAQ: NBTX) Q4 2022 earnings conference call, held 2023-04-25. Replay captured from the company's public earnings webcast.

Senior Vice President, Investor Relations
Chief Executive Officer
Chief Financial Officer
Good day, and thank you for standing by. Welcome to the Nanobiotics Business Update and Full Year 2022 Financial Results Conference Call. A slide presentation accompanying this call can be found at the investor section of the company's website at www.nanobiotics.com. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. At this point, I will turn the call over to Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations of Nanobiotics. Craig West, Senior Vice President of Investor Relations and Bart Van Ryn, Chief Financial Officer. As a reminder, today's call is being webcast and will be available on our website for replay. I would like to remind you that this call will include forward-looking statements, which may include statements regarding the progress, success, and timing of our ongoing and planned clinical trials, collaborations, regulatory fil...